Suppr超能文献

序贯血液透析与免疫吸附用于肾移植候选受者脱敏治疗的疗效及安全性

Efficacy and safety of tandem hemodialysis and immunoadsorption to desensitize kidney transplant candidates.

作者信息

Rostaing Lionel, Maggioni Sébastien, Hecht Corinne, Hermelin Martine, Faudel Eric, Kamar Nassim, Sallusto Federico, Doumerc Nicolas, Allal Asma

机构信息

From the Department of Nephrology and Organ Transplantation, University Hospital Toulouse, France; the Department of Urology, Transplantation, and Andrology; and the INSERM U563, IFR-BMT, CHU Purpan, Toulouse, France.

出版信息

Exp Clin Transplant. 2015 Apr;13 Suppl 1:165-9.

Abstract

OBJECTIVES

We conducted a desensitization program in our center in patients undergoing kidney transplant for end-stage renal disease. These patients had a living-donor either ABO incompatible and/or human-leukocyte antigen-incompatible. The safety and efficacy of this program were evaluated.

MATERIALS AND METHODS

A pretransplant desensitization program relies on immunosuppressants and apheresis to remove detrimental antibodies. We chose immunoadsorption as the apheresis technique, and coupled this with hemodialysis in a tandem procedure.

RESULTS

We report on the efficacy of this new method in 120 procedures performed in 20 patients (14 ABO incompatible, 6 ABO incompatible/human leukocyte antigen-incompatible). The tandem procedure was well tolerated, and saved time compared with conducting sequential immunoadsorption and hemodialysis (6 h vs 10 h). The tandem procedure was associated with significantly decreased isoagglutinin titers and donor-specific alloantibodies (assessed by mean fluorescence intensity). Dialysance was effective (183, 102-264). The biochemical and hematologic parameters were similar to those observed after a conventional hemodialysis session, with the exception of protidemia; this might be related to some degree of albumin loss during the immunoadsoprtion procedure. The posttransplant events included 1) one ABO incompatible / human leukocyte antigenincompatible patient with vein thrombosis and ultimate kidney loss; 2) two patients with steroidsensitive cellular acute rejection; and 3) two patients with acute antibody-mediated rejection, which was successfully treated with apheresis and steroid pulses, plus rituximab in one and eculizumab in the other.

CONCLUSIONS

We conclude that the tandem immunoadsorption-hemodialysis procedure is efficient at desensitizing patients with end-stage renal disease who are candidates for a living ABO incompatible and/or human leukocyte antigenincompatible donor-kidney transplant.

摘要

目的

我们在本中心对终末期肾病接受肾移植的患者开展了一项脱敏计划。这些患者的活体供者存在ABO血型不相容和/或人类白细胞抗原不相容的情况。对该计划的安全性和有效性进行了评估。

材料与方法

移植前脱敏计划依赖免疫抑制剂和血液分离术来清除有害抗体。我们选择免疫吸附作为血液分离技术,并将其与串联进行的血液透析相结合。

结果

我们报告了该新方法在20例患者中进行的120次操作的有效性(14例ABO血型不相容,6例ABO血型不相容/人类白细胞抗原不相容)。串联操作耐受性良好,与依次进行免疫吸附和血液透析相比节省了时间(6小时对10小时)。串联操作与异凝集素滴度和供者特异性同种抗体显著降低相关(通过平均荧光强度评估)。透析效率良好(183, 102 - 264)。生化和血液学参数与常规血液透析 session 后观察到的参数相似,但蛋白血症除外;这可能在一定程度上与免疫吸附过程中白蛋白的丢失有关。移植后事件包括:1)1例ABO血型不相容/人类白细胞抗原不相容患者发生静脉血栓形成并最终失去肾脏;2)2例患者发生类固醇敏感型细胞急性排斥反应;3)2例患者发生急性抗体介导的排斥反应,通过血液分离术和类固醇冲击成功治疗,其中1例加用利妥昔单抗,另1例加用依库珠单抗。

结论

我们得出结论,免疫吸附 - 血液透析串联操作对于使终末期肾病且有活体ABO血型不相容和/或人类白细胞抗原不相容供肾移植候选资格的患者脱敏是有效的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验